Overall, the study found that greater social support at initiation of anti-VEGF treatment was associated with reduced depression at follow-up; a decrease in self-reported visual functioning was related to higher stress level at follow-up, whereas objectively measured VA change was not. This evidence concerns the gene VEGFA and depressive symptom measurement.